DAFTAR PUSTAKA

Agnihotri, S.A., Mallikarjuna, N.N., and Aminabhavi, T.M. 2004. Recent advances on chitosan-based micro and nanoparticles in drug delivery. *J. of Controlled Release* 100: 5-28.

Bell, D. A., 2005. Origins and molecular pathology of ovarian cancer. *Mod. Pathol.* 18: 19–32.

Bhaskaran, M., & Mohan, M.2013. MicroRNAs. *Veterinary Pathology*, 51(4), 759–774.

Bindewald, E., Shapiro, B.A.2017. RNA Nano- structures. *Springer Nature*, New York.

Bruning, U., Cerone, L., Neufeld, Z., Fitzpatrick, S. F., Cheong, A., Scholz, C. C.,*et al*. 2011.MicroRNA-155 Promotes Resolution of Hypoxia-Inducible Factor 1 Activity during Prolonged Hypoxia. *Molecular and Cellular Biology*, 31(19), 4087–4096.

Calin, G.A.; Dumitru, C.D.; Shimizu, M.; Bichi, R.; Zupo, S.; Noch, E.; Aldler, H.; Rattan, S.; Keating, M.; Rai, K.; *et al*.2002. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 inchronic lymphocytic leukemia. *Proc. Natl. Acad. Sci.* USA, 99, 15524–15529.

Calin, G.A., Sevignani, C., Dumitru, C.D., Hyslop, T., Noch, E., Yendamuri, S., Shimizu, M., Rattan, S., Bullrich, F., Negrini, M., Croce, C.M., 2004. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. *Proc. Natl. Acad. Sci*. U. S. A. 101, 2999–3004.

Calin, G.A., Croce, C.M., 2009. Chronic lymphocytic leukemia: interplay between noncoding RNAs and protein-coding genes. *Blood* 114, 4761–4770.

Cao, L., Xie, B., Yang, X., Liang, H., Jiang, X., Zhang, D., *et al*. 2015. MiR-324-5p Suppresses Hepatocellular Carcinoma Cell Invasion by Counteracting ECM Degradation through Post-Transcriptionally Downregulating ETS1 and SP1. *PLOS ONE*, 10(7).

Chasanah, S.N., Fitriawan, A.S., Pukan, F.K., Kartika, A.I., Mubarika, S . 2016. The expression of miRNA-155 and hypoxia inducible factor alpha (HIF1α) mRNA in the early and advanced stages of ovarian cancer patients blood plasma. *Suppl. J Med Sci* 48: 2016.

Chen, S.-N., Chang, R., Lin, L.-T., Chern, C.-U., Tsai, H.-W., Wen, Z.-H., *et al*. 2019. MicroRNA in Ovarian Cancer: Biology, Pathogenesis, and

Therapeutic Opportunities. *International Journal of Environmental Research and Public Health*, 16(9), 1510.

Chen, W., Huang, L., Hao, C., Zeng, W., Luo, X., Li, X, *et al*. 2016 . MicroRNA-155 promotes apoptosis in SKOV3, A2780, and primary cultured ovarian cancer cells. Tumor Biology, 37(7), 9289–9299.

Chen, Y., Gao, D.-Y., & Huang, L. 2015. In vivo delivery of miRNAs for cancer therapy: Challenges and strategies. *Advanced Drug Delivery Reviews*, 81, 128–141.

Cheng, H., Xue, J., Yang, S., Chen, Y., Wang, Y., Zhu, 702 Y. et al. 2017. Co-targeting of IGF1F/mTOR pathway by miR-497 and miR-99a impairs hepatocellular carcinoma development. *Oncotarget*, 8, 47984-47997.

Chithrani, BD., Chan, WC. 2007. Elucidating The Mechanism of Cellular Uptake and Removal of Protein-Coated Gold Nanoparticles of Different Sizes and Shapes. *Nano Lett*.7 (6): 1542-1550.

Chung, K.H., Hart, C.C., Al-Bassam, S., Avery, A., Taylor, J., Patel, P.D., Vojtek, A.B., Turner, D.L., 2006. Polycistronic RNA polymerase II expression vectors for RNA interference based on BIC/miR-155. *Nucleic Acids Res*. 34, e53.

Ciucci, A., De Stefano, I., Vellone, V. G., Lisi, L., Bottoni, C., Scambia, G., Gallo, D. 2013. Expression of the Glioma-Associated Oncogene Homolog 1 (Gli1) in Advanced Serous Ovarian Cancer Is Associated with Unfavorable Overall Survival. *PLoS ONE, 8(3), e60145.*

Corney, D.C., Nikitin, A.Y., 2008. microRNA and Ovarian Cancer. *Histol Histopathol.* 23: 1161–1169.

Cosco, D., Cilurzo, F., Maiuolo, J., Federico, C., Di Martino, M. T., Cristiano, M. C., Paolino, D. 2015. Delivery of miR-34a by chitosan/PLGA nanoplexes for the anticancer treatment of multiple myeloma. *Scientific Reports*, 5(1).

Cui, J.G.; Zhao, Y.; Sethi, P.; Li, Y.Y.; Mahta, A.; Culicchia, F.; Lukiw, W.J. 2010. Micro-RNA-128 (miRNA-128) down-regulation in glioblastoma targets ARP5 (ANGPTL6), Bmi-1 and E2F-3a, key regulators of brain cell proliferation. *J. Neuro-Oncol*, 98, 297–304.

Csaba, N.; Köping-Höggård, M.; Alonso, M.J.2009.Ionically crosslinked chitosan/tripolyphosphate nanoparticles for oligonucleotide and plasmid DNA delivery. *Int. J. Pharm*. 382, 205–214.

Deb, B., Uddin, A., & Chakraborty, S. 2017. miRNAs and ovarian cancer: An overview. *Journal of Cellular Physiology*, 233(5), 3846–3854.

Deng, X., Cao, M., Zhang, J., Hu, K., Yin, Z., Zhou, Z., Yang, Y., Sheng, W., Wu, Y., Zeng, Y., 2014. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer. *Biomaterials* 35 (14), 4333–4344.

Denizli, M., Aslan, B., Mangala, L. S., Jiang, D., Rodriguez-Aguayo, C., Lopez-Berestein, G., & Sood, A. K. 2017. Chitosan Nanoparticles for miRNA Delivery. *Methods in Molecular Biology*, 219–230.

Di Leva, G., & Croce, C. M.2013. The role of microRNAs in thetumorigenesis of ovarian cancer. *Frontiers in Oncology*, 3, 153.

De Lima, A. B., Silva, L. M., Gonçales, N. G., Carvalho, M. R. S., da Silva Filho, A. L., & da Conceição Braga, L. 2018. Three-Dimensional Cellular Arrangement in Epithelial Ovarian Cancer Cell Lines TOV-21G and SKOV-3 is Associated with Apoptosis-Related miRNA Expression Modulation. *Cancer Microenvironment*, 11(1), 85–92.

Du, Z., Hu, L., Wang, H., Yan, L., Zeng, Y., Shao, J.,2011. Upregulation of MiR-155 in Nasopharyngeal Carcinoma is Partly Driven by LMPI and LMP2A and Downregulates a Negative Prognostic Marker JMJD1A. *Plos One 6*.

Ferretti E, De Smaele E, Miele E, et al. 2008. Concerted microRNA control of hedgehog signalling in cerebellar neuronal progenitor and tumour cells. *Embo J* ; 27:2616–27.

Ganju, A., Khan, S., Hafeez, B.B., Behrman, S.W., Yallapu, M.M., Chauhan, S.C., Jaggi, M., 2017. miRNA nanotherapeutics for cancer. *Drug Discov. Today* 22: 424–432.

Gaur, S., Wen, Y., Song, J.H., Parikh, N.U., Mangala, L.S., Blessing, A.M., Ivan, C., Wu, S.Y., Varkaris, A., Shi, Y., Lopez-Berestein, G., Frigo, D.E., Sood, A.K., Gallick, G.E., 2015. Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy. *Oncotarget 6*, 29161–29177.

Han HD, Mangala LS, Lee JW, Shahzad MM, Kim HS, Shen D, Nam EJ, Mora EM, Stone RL, Lu. 2010. Targeted gene silencing using RGD-labeled chitosan nanoparticles. *Clin Cancer Res* 16(15):3910–3922.

Imanuel, T.Gea, Maria F.Loho, Freddy W.Wagey. 2016. Gambaran jenis kanker ovarium di RSUP Prof. Dr. R.D Kandou Manado periode Januari 2013 – Desember 2015. *Jurnal e-Clinic*, Volume 4, Nomor 2.

Iorio, M.V.; Visone, R.; Di Leva, G.; Donati, V.; Petrocca, F.; Casalini, P.; Taccioli, C.; Volinia, S.; Liu, C.G.; Alder, H.; *et al*. 2007. MicroRNA signatures in human ovarian cancer. *Cancer Res*, 67, 8699–8707.

Irianto, Hari Eko., Mujanah, I. 2011. Proses Dan Aplikasi Nanopartikel Kitosan Sebagai Penghantar Obat. *Squalen* Vol.6: 1-8.

Iswanda, R., Anwar,E., Jufri,M. 2013.Formulasi Nanopartikel Verapamil Hidroklorida dari Kitosan dan Natrium Tripolifosfat dengan Metode Gelasi Ionik. *Jurnal Farmasi Indonesia*, Vol.6 No.4.

Jiang, H., & Feng, Y.2006. Hypoxia-inducible factor 1α (HIF-1α) correlated with tumor growth and apoptosis in ovarian cancer. *International Journal of Gynecological Cancer*, 16(S1), 405–412.

Juwita., *et al*. l2017. MicroRNA-21, MicroRNA-155 dan MicroRNA-10B: Bagaimana Perannya Pada Kanker Payudara. *Jurnal Kedokteran Syiah Kuala*, volume 17, number 2, pages: 119-125.

Kampono N. 2011. Tumor ganas alat genital Kanker ovarium. In: Anwar M, Baziad A, Prabowo R, editors. Ilmu Kandungan (3rd). Jakarta: Bina Pustaka Sarwono Prawirohardjo;p. 307-11

Kinose, Y., Sawada, K., Nakamura, K., & Kimura, T. 2014. The Role of MicroRNAs in Ovarian Cancer. *BioMed Research International*, 2014, 1–11.

Krutzfeldt, J., Rajewsky, N., Braich, R., Rajeev, K.G., Tuschl, T., Manoharan, M., Stoffel, M., 2005. Silencing of microRNAs in vivo with 'antagomirs'. *Nature* 438, 685–689.

Kumar, M.S.; Erkeland, S.J.; Pester, R.E.; Chen, C.Y.; Ebert, M.S.; Sharp, P.A.; Jacks, T. 2008. Suppression of non-small cell lung tumor development by the let-7 microRNA family. *Proc. Natl. Acad. Sci.* USA, 105,3903–3908.

Laili, H.N., Winarti, L., Sari, L.O.R.K. 2014. Preparasi dan Karakterisasi Nanopartikel Kitosan-Naringenin dengan Variasi Rasio Massa Kitosan-Natrium Tripolifosfat. *E-Jurnal Pustaka Kesehatan*, vol.2 no.2.

L Hollis, R., L Hollis, R., Gourley, C., & Gourley, C. 2016. Genetic and molecular changes in ovarian cancer. *Cancer Biology & Medicine*, 13(2), 236–247.

Lee, S. H., Jung, Y. D., Choi, Y. S. and Lee, Y. M. 2015. Targeting of RUNX3 by miR-130a and 817 miR-495 coorepatively increases cell proliferation and tumor angiogenesis in gastric cancer cells. *Oncotarget*, 6, 33269-33278.

Li, S., Zhang, T., Zhou, X., Du, Z., Chen, F., Luo, J., & Liu, Q. 2018. The tumor suppressor role of miR-155-5p in gastric cancer. *Oncology Letters*.

Li, Y.T.; Lee, W.L.; Tsui, K.H. 2016. Endometrial thickness still presents a best reference to predict endometrial cancer. Taiwan. *J. Obstet. Gynecol* , 55, 148–149.

Lin, M., Chen, Y., Lee, M., Weng, K., Chang, H., Yu, S., *et al* .2018. Comprehensive identification of microRNA arm selection preference in lung cancer: miR-324-5p and -3p serve oncogenic functions in lung cancer. *Oncology Letters*.

Liu YP, Berkhout B. 2011. MiRNA cassettes in viral vectors: problems andsolutions. *Biochim Biophys Acta*. 1809(11–12):732–45.

Liu, X., Yao, B., & Wu, Z. (2018). miRNA-199a-5p suppresses proliferation and invasion by directly targeting NF-κB1 in human ovarian cancer cells. Oncology Letters.

Lujambio, A., Ropero, S., Ballestar, E., Fraga, M.F., Cerrato, C., Setien, F., Casado, S., Suarez-Gauthier, A., Sanchez-Cespedes, M., Git, A., Spiteri, I., Das, P.P., Caldas, C., Miska, E., Esteller, M., 2007. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. *Cancer Res*. 67, 1424–1429.

Luo, P.; Fei, J.; Zhou, J.; Zhang,W. 2015. microRNA-126 suppresses PAK4 expression in ovarian cancer SKOV3 cells. *Oncol. Lett*, 9, 2225–2229.

Mastrangelo, E., & Milani, M.2018. Role and inhibition of GLI1 protein in cancer. *Lung Cancer: Targets and Therapy*, Volume 9, 35–43.

M. Caffo, V. Barresi, G. Caruso, M. Cutugno, G. La Fata, M. Venza, C. Alafaci, F. Tomasello. 2013. Innovative therapeutic strategies in the treatment of brain metastases, *Int. J. Mol. Sci*. 14 2135–2174.

M.D. Jansson, A.H. Lund. 2012. MicroRNA and cancer, *Mol. Oncol*. 6 590–610.

M. V. Iorio, R. Visone, G. Di Leva. 2007.MicroRNA signaturesin human ovarian cancer. *Cancer Research*, vol. 67, no. 18, pp.8699–8707.

Miroshnichenko S and Patutina O. 2019. Enhanced inhibition of tumorigenesis using combinations of miRNA-targeted therapeutics. *Front. Pharmacol*. 10:488.

Naidu, S., Magee, P., & Garofalo, M. 2015 . MiRNA-based therapeutic intervention of cancer. *Journal of Hematology & Oncology*, 8(1).

Negrini, M., Ferracin, M., Sabbioni, S., Carlo, M.C. 2007. MicroRNAs in cancer: from research to therapy. J. *Cell Sci*. 120: 1833-1840.

Nishimura,M., Jung, E.J., Shah,M.Y., Lu, C., Spizzo, R., Shimizu,M., Han, H.D., Ivan, C., Rossi, S., Zhang, X., Nicoloso, M.S., Wu, S.Y., Almeida, M.I., Bottsford-Miller, J., Pecot, C.V., Zand, B., Matsuo, K., Shahzad, M.M., Jennings, N.B., Rodriguez- Aguayo, C., Lopez-Berestein, G., Sood, A.K., Calin, G.A., 2013. Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. *Cancer Discov* 3,1302–1315.

Niles, A. L., Moravec, R. A., & Riss, T. L. 2008. Update onin vitrocytotoxicity assays for drug development. Expert Opinion on *Drug Discovery*, 3(6), 655–669.

Nguyen, L., T., Atobe, K., Barichello, J., M., Ishida, T., Kiwada, H. 2007. Complex formation with plasmid DNA increases the cytotoxicity of cationic liposomes. *Biol.Pharm.Bull*., 30(4)":751-7.

Nurasih, A.D., Mubarika, S., Astuti, I. 2018. Pengembangan dan pengujian target terapi mimic miR-155-5p dan Antagonist miR-324-5p pada kultur sel kanker ovarium SCOV3. *Tesis* S2 Bioteknologi Universitas Gadjah Mada, Yogyakarta.

Purwoko, M. 2018. Hubungan Tingkat Pendidikan Dan Pekerjaan Dengan Tingkat Pengetahuan Mengenai Kanker Ovarium Pada Wanita. *Mutiara Medika: Jurnal Kedokteran dan Kesehatan*. Vol 18 No.2.

Qin W, Ren Q, Liu T, Huang Y,Wang J. 2013.MicroRNA-155 is a novel suppressor of ovarian cancer-initiating cells that targets cldn1.*FEBS Lett*.;587:1434–9.

Ragelle H, Vandermeulen G, Pre´at V. 2013.Chitosan-based siRNA delivery systems. *J Control Release* 172(1):207–218.

Rakheja, D., Chen, K.S., Liu, Y., Shukla, A.A., Schmid, V., Chang, T.C., Khokhar, S., Wickiser, J.E., Karandikar, N.J., Malter, J.S., Mendell, J.T., Amatruda, J.F., 2014. Somaticmutations in DROSHA and DICER1 impair microRNA biogenesis through distinct mechanisms in Wilms tumours. *Nat. Commun*. 2, 4802.

Sahoo, S., K., Labhasetwar, V. 2003. Nanotech Approaches to Drug Delivery and Imaging, *Drug Discov Today*, 8:1112-1120.

Santos-Carballal, B., Aaldering, L.J., Ritzefeld, M., Pereira, S., Sewald, N., Moerschbacher,B.M., Gotte, M., Goycoolea, F.M., 2015. Physicochemical and biological characterizationof chitosanmicroRNA nanocomplexes for gene delivery to MCF-7 breast cancer cells. *Sci. Rep*. 5, 13567.

Shah, M. Y., Ferrajoli, A., Sood, A. K., Lopez-Berestein, G., & Calin, G. A. 2016. microRNA. Therapeutics in Cancer — An Emerging Concept. *EBioMedicine*, 12, 34–42.

Stordal, B.; Hamon, M.; McEneaney, V.; Roche, S.; Gillet, J.P.; O'Leary, J.J.; Gottesman, M.; Clynes, M. 2012. Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein. *PLoS ONE*, 7, e40717.

Sumadi, F.A.N., Mubarika, S., Martien, R. 2018. Formulasi Nanopartikel Kitosan Berbasis Mikrorna Sebagai Terapi Tertarget Molekular Pada Kultur Sel Kanker Ovarium SKOV3. *Tesis* S2 Bioteknologi Universitas Gadjah Mada, Yogyakarta.

Sun, G.-L., Li, Z., Wang, W.-Z., Chen, Z., Zhang, L., Li, Q *et al*. 2017. miR-324-3p promotes gastric cancer development by activating Smad4-mediated Wnt/beta-catenin signaling pathway. *Journal of Gastroenterology*, 53(6), 725–739.

Tang, B., Xu, A., Xu, J., Huang, H., Chen, L., Su, Y. *et al*. 2017. MicroRNA-324-5p regulates stemness, pathogenesis and sensitivity to bortezomib in multiple myeloma cells by targeting hedgehog signaling. *International Journal of Cancer*, 142(1), 109–120.

Tang, B., Xu, A., Xu, J., Huang, H., Chen, L., Su, Y., Zhang, L., Li, J., Fan, F., Deng, J., Tang, L., Sun, C., Hu, Y., 2018. MicroRNA-324-5p regulates stemness, pathogenesis and sensitivity to bortezomib in multiple myeloma cells by targeting hedgehog signaling. *Int. J. Cancer* 142: 109–120.

Thomson, D.W., Bracken, C.P., Szubert, J.M., Goodall, G.J. 2013. On measuring miRNAs after Transient Transfection of Mimics or Antisense Inhibitors. *PLoS One* 8:1-7.

Ulrich H.Weidle, Fabian Birzele, Gwen Kollmorgen, Adam Nopora. 2018. Potential microRNA-related targets for therapeutic intervention with ovarian cancer metastatis. *Cancer Genomics & Proteomics* 15: 1-15.

Walker, J.M., 2009. Micro and Nano Technologies in Bioanalysis : Method and Protocol. Humana Press, Hertfordshire, UK.

Winarti, L. 2011. Review Artikel: Penggunaan Formulasi Nanopartikel Kitosan Sebagai Sistem Penghantaran Gen Non Viral Untuk Terapi Gen. *Stomatognatic* (J. K. G Unej) Vol. 10 No.2 : 93-98.

Winarti, L., Martien, R., Sismindari. 2013. Potensi Penggunaan Kitosan Rantai Pendek Sebagai Pembawa Dalam Penghantaran Gen: Evaluasi In Vitro. *Stomatognatic* (J. K. G Unej) Vol. 10 No.2 : 93-98.

Xu, H.S., Zong, H.L., Shang, M., Ming, X., Zhao, J.P., Ma, C., Cao, L. 2014. MiR-324-5p inhibits proliferation of glioma by target regulation of GLI1. *Eur. Rev. Med. Pharmacol. Sci*. 18: 828-832.

Yamamoto, N.; Nishikawa, R.; Chiyomaru, T.; Goto, Y.; Fukumoto, I.; Usui, H.; Mitsuhashi, A.; Enokida, H.;Nakagawa, M.; Shozu, M.; et al. 2015. The tumor-suppressive microRNA-1/133a cluster targets PDE7A and inhibits cancer cell migration and invasion in endometrial cancer. *Int. J. Oncol*, 47, 325–334.

Yu HL, Kiran S, Kurt ML, Jyuhn HJ, Fwu LM, Han WY, dan Hsing WS.2008. Multi-ion-crosslinked nanoparticles with pH-responsive characteristics for oral delivery of protein drugs. *Journal of Controlled Release*; 132: 141-149.